IBDEI15Z ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20822,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20822,1,1,0)
 ;;=1^205.10
 ;;^UTILITY(U,$J,358.3,20822,1,8,0)
 ;;=8^Chr Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,20822,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,20823,0)
 ;;=205.11^^118^1255^17
 ;;^UTILITY(U,$J,358.3,20823,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20823,1,1,0)
 ;;=1^205.11
 ;;^UTILITY(U,$J,358.3,20823,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,20823,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,20824,0)
 ;;=289.0^^118^1255^50
 ;;^UTILITY(U,$J,358.3,20824,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20824,1,1,0)
 ;;=1^289.0
 ;;^UTILITY(U,$J,358.3,20824,1,8,0)
 ;;=8^Secondary Polycythemia
 ;;^UTILITY(U,$J,358.3,20824,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,20825,0)
 ;;=238.4^^118^1255^48
 ;;^UTILITY(U,$J,358.3,20825,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20825,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,20825,1,8,0)
 ;;=8^Polycythemia Rubra Vera
 ;;^UTILITY(U,$J,358.3,20825,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,20826,0)
 ;;=288.9^^118^1255^67
 ;;^UTILITY(U,$J,358.3,20826,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20826,1,1,0)
 ;;=1^288.9
 ;;^UTILITY(U,$J,358.3,20826,1,8,0)
 ;;=8^Unspecified Dis Of W B C
 ;;^UTILITY(U,$J,358.3,20826,2)
 ;;=^267993
 ;;^UTILITY(U,$J,358.3,20827,0)
 ;;=289.81^^118^1255^49
 ;;^UTILITY(U,$J,358.3,20827,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20827,1,1,0)
 ;;=1^289.81
 ;;^UTILITY(U,$J,358.3,20827,1,8,0)
 ;;=8^Primary Hypercoagulable State
 ;;^UTILITY(U,$J,358.3,20827,2)
 ;;=^329886
 ;;^UTILITY(U,$J,358.3,20828,0)
 ;;=238.75^^118^1255^29
 ;;^UTILITY(U,$J,358.3,20828,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20828,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,20828,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,20828,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,20829,0)
 ;;=289.9^^118^1255^66
 ;;^UTILITY(U,$J,358.3,20829,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20829,1,1,0)
 ;;=1^289.9
 ;;^UTILITY(U,$J,358.3,20829,1,8,0)
 ;;=8^Unspecified Blood Disease
 ;;^UTILITY(U,$J,358.3,20829,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,20830,0)
 ;;=205.02^^118^1255^30
 ;;^UTILITY(U,$J,358.3,20830,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20830,1,1,0)
 ;;=1^205.02
 ;;^UTILITY(U,$J,358.3,20830,1,8,0)
 ;;=8^Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,20830,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,20831,0)
 ;;=205.12^^118^1255^16
 ;;^UTILITY(U,$J,358.3,20831,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20831,1,1,0)
 ;;=1^205.12
 ;;^UTILITY(U,$J,358.3,20831,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,20831,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,20832,0)
 ;;=205.20^^118^1255^59
 ;;^UTILITY(U,$J,358.3,20832,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20832,1,1,0)
 ;;=1^205.20
 ;;^UTILITY(U,$J,358.3,20832,1,8,0)
 ;;=8^Subacute Myeloid Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,20832,2)
 ;;=^336857
 ;;^UTILITY(U,$J,358.3,20833,0)
 ;;=205.21^^118^1255^58
 ;;^UTILITY(U,$J,358.3,20833,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20833,1,1,0)
 ;;=1^205.21
 ;;^UTILITY(U,$J,358.3,20833,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,20833,2)
 ;;=^267536
 ;;^UTILITY(U,$J,358.3,20834,0)
 ;;=205.22^^118^1255^57
 ;;^UTILITY(U,$J,358.3,20834,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20834,1,1,0)
 ;;=1^205.22
 ;;^UTILITY(U,$J,358.3,20834,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,20834,2)
 ;;=^336472
 ;;^UTILITY(U,$J,358.3,20835,0)
 ;;=205.30^^118^1255^35
 ;;^UTILITY(U,$J,358.3,20835,1,0)
 ;;=^358.31IA^8^2
